Vaccines

New data demonstrates protection against new variants.

The origins of the recent H5N1 (avian flu) case in Texas remain unknown, but a researcher offers insights into transmission between animals and humans, the likelihood of more cases, vaccine availability, and treatment.

The company is going to submit their data to the FDA to seek approval for people within this age group.

A study on Italian vaccination rates and factors influencing Rotavirus vaccine acceptance.

Trial examines high-dose vs. standard-dose influenza vaccines.

As a potential alternative to antibiotic treatments, this investigational immunization offered protection for several years.

During the 2014-2016 African epidemic, investigational Ebola vaccines demonstrated safety and immunogenicity.

An FDA decision on the company’s mRNA-1345 is slated for May 12.

The RSV prefusion F protein–based maternal vaccine phase 3 trial was halted due to the risk of this adverse event.

Bavarian Nordic's JYNNEOS available to healthcare providers nationwide.

This very large study reviewed data, which showed people vaccinated for the virus had a substantial reduction of risk for these types of events.

The company's latest investigational vaccine induced a greater immune response compared to its FDA approved Spikevax product.

A large European study looked at a modern-day communication method and its influence on a public health initiative to increase immunizations.

The Bill & Melinda Gates Medical Research Institute launches the M72/AS01E vaccine in South Africa to combat TB.

The company’s investigational vaccine, V116, is a conjugate vaccine and demonstrated immunogenicity for all 21 serotypes across the studied adult groups.

Since changes in vaccine composition can sometimes lead to confusion or misinformation, effective communication is crucial to promote vaccine uptake.

A new study shows how correcting misinformation in a certain way can change patients’ attitudes towards vaccination.

It is not simply just a few cases are springing up, but rather that transmission is occurring, and behind a backdrop of vaccine skepticism.

Public health strategy in navigating flu season.

With today's vote, the federal agency’s Advisory Committee on Immunization Practices (ACIP) is now recommending people 65 years of age and older get 1 more dose of the 2023-2024 formula of the COVID-19 vaccine.

The mRNA-1647 vaccine demonstrated approximately a 50% efficacy against human cytomegalovirus (HCMV).

The self-amplifying mRNA vaccine, ARCT-154, had an extended response compared to the BNT162b2 vaccine and was approved in Japan back in November.

Study will determine the effectiveness of vaccine in preventing invasive pneumococcal disease.

This news comes after the World Health Organization (WHO) recently granted the vaccine an emergency use listing (EUL), and continues to become available to more countries.

A new study reveals that the cholera vaccine's diminished efficacy highlights the need for improved strategies in combating a global health challenge.

The National Foundation for Infectious Diseases (NFID) medical director weighs in on this year’s respiratory virus season and offers some strategies to prevent transmission.

New study reinforces the importance of early detection and vaccination against bacterial meningitis.

Changes encompass clarification of recommendations for scheduled vaccinations and the addition of the RSV vaccines for the first time.

With it comes the possibility for international cooperation regarding an investigational Middle East Respiratory Syndrome (MERS) vaccine.

A new human trial aims to prevent the fatal, zoonotic-borne disease.